Moderna, Inc. - Common Stock (MRNA)

191.22
-12.24 (-6.02%)
NASDAQ · Last Trade: Sep 30th, 4:06 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close203.46
Open186.55
Bid191.22
Ask191.40
Day's Range184.58 - 196.83
52 Week Range22.28 - 208.90
Volume17,076,695
Market Cap75.34B
PE Ratio (TTM)-26.30
EPS (TTM)-7.3
Dividend & YieldN/A (N/A)
1 Month Average Volume15,194,704

Chart

About Moderna, Inc. - Common Stock (MRNA)

Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More

News & Press Releases

Prediction: Moderna Stock Will Soar 100% by 2030fool.com
The company could enter a fresh growth phase.
Via The Motley Fool · September 30, 2026
Top S&P500 movers in Wednesday's sessionchartmill.com
Via Chartmill · September 30, 2026
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Via Chartmill · September 30, 2026
Why Moderna (MRNA) Shares Are Falling Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutr...
Via StockStory · September 30, 2026
These S&P500 stocks are moving in today's pre-market sessionchartmill.com
Via Chartmill · September 30, 2026
Wednesday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · September 30, 2026
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna
By Moderna, Inc. · Via ACCESS Newswire · September 30, 2026
2 S&P 500 Stocks to Consider Right Now and 1 We Question
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Via StockStory · September 29, 2026
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?fool.com
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase.
Via The Motley Fool · September 28, 2026
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?fool.com
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.
Via The Motley Fool · September 28, 2026
These S&P500 stocks that are showing activity before the opening bell on Monday.chartmill.com
Via Chartmill · September 28, 2026
Discover which S&P500 stocks are making waves on Thursday.chartmill.com
Via Chartmill · September 24, 2026
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVIDmarketbeat.com
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office
Via MarketBeat · September 23, 2026
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?fool.com
The company is looking to prove it can achieve significant success outside the coronavirus market.
Via The Motley Fool · September 22, 2026
Is Moderna Stock a Buy After Its Melanoma Breakthrough?fool.com
Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves, what could come next, and where the biggest risk still sits.
Via The Motley Fool · September 22, 2026
Discover which S&P500 stocks are making waves on Tuesday.chartmill.com
Via Chartmill · September 22, 2026
These S&P500 stocks are moving in today's sessionchartmill.com
Via Chartmill · September 22, 2026
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."fool.com
Following last month's super rally, a growing number of analysts are now calling for caution.
Via The Motley Fool · September 22, 2026
Discover the top S&P500 movers in Tuesday's pre-market session.chartmill.com
Via Chartmill · September 22, 2026
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?fool.com
Investors buying this biotech stock now will get its pipeline essentially for free.
Via The Motley Fool · September 22, 2026
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Tradechartmill.com
Via Chartmill · September 22, 2026
Monday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · September 21, 2026
Moderna (MRNA) Stock Trades Up, Here Is Why
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results ...
Via StockStory · September 21, 2026
Discover which S&P500 stocks are making waves on Monday.chartmill.com
Via Chartmill · September 21, 2026
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT
By Moderna, Inc. · Via ACCESS Newswire · September 21, 2026